港股异动 | 中国生物制药收复昨日失地涨逾7% 股价刷新年内新高
格隆汇8月29日丨中国生物制药(1177.HK)经过昨日小幅调整后重回升势,现涨7.16%,报11.38港元,盘中最高见11.42港元刷新年内高点,暂成交8.88亿港元,最新总市值1433亿港元。公司昨日公告称,截至2019年6月30日止6个月收入125.27亿元人民币(下同),同比增28.8%;归属于母公司持有者应占盈利14.44亿元,同比增5.8%;拟派中期股息每股4港仙。期内,公司借重磅1类原创新药福可维新上市契机,销量持续强势增长,同时带动依固、依尼舒、首辅、赛维健等其他肿瘤相关产品快速增长。新上市用于成年多发性骨髓瘤产品安显(来那度胺胶囊)、治疗复发或难治性套细胞淋巴瘤产品千平(注射用硼替佐米)上市后销售表现优异,增长迅速。花旗研报指,维持中国生物制药“买入”评级,目标价13.2港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.